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ABSTRACT 
Congestive heart failure (CHF) is a major cause of morbidity and mortality with an 
increasing prevalence in human and canine populations. Similar to humans, 
overactivation of the renin-angiotensin aldosterone system is involved in the 
pathophysiology of CHF in dogs. Current therapeutic strategies for the management of 
canine CHF include the use of RAAS inhibitors, diuretics and inodilators. The present 
review summarizes data from our own research on the modulation of the renin-
angiotensin cascade in dogs in dogs, together with new findings (including novel 
therapeutic targets) from the veterinary and the human literature. 
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ABBREVIATIONS 
ACE Angiotensin-converting enzyme 
AI Angiotensin I 
AII Angiotensin II 
ALD Aldosterone 
ARB Angiotensin receptor blocker 
ARNI Angiotensin receptor neprilysin inhibitor 
ASI Aldosterone synthase inhibitor 
AT1R AII type 1 receptor 
BP Blood pressure 
cGMP Cyclic GMP 
CHAT Circadian hyper-amplitude-tension 
CHF Congestive heart failure 
CKD Chronic kidney disease 
DCM Dilated cardiomyopathy 
EG Empaglifozin 
GR Glucocorticoid receptor 
HFpEF Heart failure with preserved ejection fraction 
HFrEF Heart failure with reduced ejection fraction 
HT Hypertension 
MMVD Myxomatous mitral valve disease 
MRA Mineralocorticoid receptor antagonist 
NLME Nonlinear mixed-effects 
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NP Natriuretic peptide 
OM Omecamtive mecarbil 
PK Pharmacokinetics 
PD Pharmacodynamics 
PCP Procollagen type I Carboxy-terminal Proteinase 
RA Renin activity 
RAAS Renin-angiotensin-aldosterone system 
RI Renin inhibitor 
U2 Urocortin-2 
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Pathophysiology of Congestive Heart Failure in Dogs 1 
Congestive heart failure (CHF) is a major cause of morbidity and mortality with an 2 
increasing prevalence in human and canine populations (Guglielmini, 2003; George et 3 
al., 2014). It is widely estimated that 10% of dogs examined by veterinarians have some 4 
form of heart disease. The two most common acquired heart disorders in dogs are 5 
degenerative mitral valve disease (DMVD, also referred to as MMVD) and dilated 6 
cardiomyopathy (DCM). Within these diseases, it is estimated that approximately 30% of 7 
dogs with MMVD and 70-80% of dogs with DCM will eventually develop CHF (Borgarelli 8 
et al., 2008; Calvert et al., 1997), suggesting that up to 1 in 20 dogs may be affected by 9 
this clinical syndrome. Prognosis for CHF in dogs ranges from 6-14 months, depending 10 
on underlying disease and other patient and comorbid factors (O’Grady et al., 2008). 11 
MMVD is characterized by thickening and shortening of the atrioventricular valves, and 12 
affects about 75% of dogs over the age of 16 (Guglielmini, 2003). While MMVD has been 13 
recognized in dogs for over a century, histopathological and clinical studies have not been 14 
able to reveal its cause or why it occurs ten times more frequently in dogs than in humans 15 
(Borgarelli & Buchanan, 2012).  16 
In humans, left ventricular ejection fraction (EF; derived as the ratio of the stroke volume 17 
and the end-diastolic volume) is used to define two types of patient populations with heart 18 
failure (HF): HF with reduced (< 40%) EF (HFrEF) vs. HF with preserved EF (HFpEF). 19 
This distinction is key as EF is an important prognostic factor in HF, and HFpEF patients 20 
(approximately 50% of HF cases worldwide) are known to respond differently to available 21 
therapies (Clevand and Clark, 2012).  22 
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Essentially, HFpEF patients present with a degree with diastolic dysfunction, analogous 23 
to what is being described in dogs with MMVD. However, in humans, HFpEF is usually a 24 
primary diastolic dysfunction issue rather than a valvular disease causing volume 25 
overload, as seen in dogs with MMVD. At the other hand of the spectrum, HFrEF, also 26 
referred to as systolic HF is analogous to canine DCM, although DCM is primarily due 27 
to myocardial dysfunction rather than ischemic heart disease like in humans. 28 
Noteworthily, HFpEF has been defined as a systemic syndrome, affecting multiple organ 29 
systems and rooted in immune dysregulation and systemic inflammation (Patel and Shah, 30 
2019). Several comorbidities, including CBD, diabetes mellitus, obesity and other chronic 31 
inflammatory diseases have therefore been associated with HFpEF. This is important as 32 
the therapeutic management of HFpEF is geared towards integration of these various 33 
components. Importantly, there are currently no approved drugs for the treatment of 34 
HFpEF. 35 
Similar to humans, the β-myosin heavy chain isoforms predominate in the dog 36 
myocardium (Hasenfuss, 1998), such that the excitation/contraction coupling in the 37 
myocardium of dogs appears to be similar to that in the human myocardium. More 38 
importantly, the pathophysiological cascade of renin activation, as observed in the course 39 
of CHF, is similar between dogs and humans, which motivated the choice of this animal 40 
species in the experimental work on the renin-angiotensin-aldosterone system (RAAS) 41 
and blood pressure (BP) pioneered by Guyton, Hall and co-workers (Cowley & Guyton, 42 
1972; Guyton et al., 1972; McCaa et al., 1975; Young & Guyton, 1977; DeClue et al., 43 
1978; Lohmeier et al., 1978; Hall et al., 1980, 1984; Wilczynski & Osmond, 1983). Renin 44 
release from the juxtaglomerular apparatus is a common compensatory mechanism to 45 
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the reduced cardiac output observed in symptomatic stages of canine and human heart 46 
failure (Watkins et al., 1976; Hall, 1991). Recognition of the dysregulation of the RAAS in 47 
the pathophysiology of CHF has led to significant medical advances (McMurray et al., 48 
2012). Reduction of angiotensin II (AII) and aldosterone (ALD) levels is paramount to 49 
prevent life-threatening complications associated with myocardial fibrosis and systemic 50 
hypertension.  51 
An Overview of the Renin-Angiotensin Aldosterone System: Past and Present 52 
A Complex and Highly-Regulated Machinery 53 
Various authors have amply reviewed the role of the RAAS in the regulation of BP and 54 
volume homeostasis (Ferrario & Strawn, 2006; Moon, 2013; Sayer & Bhat, 2014). The 55 
expression of certain RAAS components even in simple organisms like crustaceans, 56 
insects and leeches underscores the importance of the renin cascade in the control of 57 
cell volume and water homeostasis throughout evolution (De Mello, 2014). The history of 58 
the RAAS and its discovery has recently been retraced with great accuracy in a review 59 
paper by Tsukamoto & Kitakaze (2013).  60 
A common description of the functioning of the systemic RAAS cascade begins with the 61 
release of renin from granular cells of the juxtaglomerular apparatus, in response to 62 
changes in sodium chloride concentrations, decreased renal blood flow, and sympathetic 63 
stimulation. Many studies have established that renin secretion is inversely related to 64 
renal perfusion pressure (Hackenthal et al., 1990; Bock et al., 1992), while β-adrenergic 65 
activation has been shown to stimulate renin release in several species, including the dog 66 
(Lew & Summers, 1987). Renin catalyzes the conversion of the precursor 67 
angiotensinogen to angiotensin I (AI), which in turn is converted to the octapeptide AII 68 
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by the angiotensin-converting enzyme (ACE) as it passes through the pulmonary 69 
capillaries. Enzymes other than ACE may contribute to the conversion of AI to AII. 70 
Chymase, cathepsin G, tonin and other proteases have been described as alternative 71 
pathways of AII production (Weber et al., 1995; Roig et al., 2000). AII is a potent 72 
vasoconstrictor with additional endocrine (e.g. ALD and arginine vasopressin secretion), 73 
neuronal (e.g. sympathetic noradrenaline release), and renal (e.g. glomerular filtration 74 
rate modulation) actions (Tsukamoto & Kitakaze, 2013). The majority of these effects are 75 
mediated through selective binding of AII to AT1 receptors. In most cases AT2 receptors 76 
binding elicits vasodilation, but cardiomyocyte hypertrophy and cell death have also been 77 
reported with stimulation of AT2 receptors (Henrion et al., 2001). Aldosterone secretion 78 
from adrenocortical cells of the zona glomerulosa contributes to body fluid and acidobasic 79 
homeostasis via sodium, potassium and hydrogen ion exchanges in the distal renal 80 
tubules and collecting ducts of Bellini (Quinn & Williams, 1988). Note that the effect of 81 
ALD on the regulation of natriuresis and BP would be quantitatively less important than 82 
the action of AII on proximal tubular sodium reabsorption. This direct intrarenal effect of 83 
AII further results in reduced urinary flow in the tubular segments of the medulla, thereby 84 
increasing medullary osmolality and fluid reabsorption in the descending loop of Henle 85 
and the collecting ducts of Bellini (Hall, 1991).  86 
Next to the systemic (circulatory) renin cascade, several RAAS components are also 87 
produced at the tissue level, in the heart, the vascular endothelium, or the kidneys 88 
(Danser, 1996; Danser et al., 1997). This ‘local RAAS’ functions as an autocrine or 89 
paracrine system and regulates tissue growth and repair processes. It is now recognized 90 
that the conventional renin/ACE/AII/AT1 cascade is no longer the sole signaling pathway 91 
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of the RAAS. At least 3 new axes have recently been identified in the kidneys and other 92 
tissues (Zhuo et al., 2013). These include: i) the ACE2/ANG(1-7)/Mas receptor pathway, 93 
that may play an opposing role to the renin/ACE/AII/AT1 axis (Esteban et al., 2009), ii) 94 
the prorenin/PRR/MAP kinases ERK1/2 axis, which appears to be pivotal in the 95 
development of diabetic nephropathy in rodents (Ichihara et al., 2004, 2006), and iii) the 96 
ANGIV/AT4/IRAP cascade, whose implication in the regulation of BP and renal 97 
modulation remains controversial. With the discovery of these additional pathways, the 98 
action of the RAAS has been extended beyond the regulation of BP, sodium and fluid 99 
homeostasis by the AT1 receptor.  100 
RAAS Activation in Vascular Inflammation, Remodeling and Congestive Heart Failure 101 
Excessive activation of the RAAS plays an essential role in vascular inflammation and 102 
remodeling (Pacurari et al., 2014). Animal and human studies have shown that AII 103 
possesses pro-inflammatory actions by regulating the expression of cytokines and 104 
chemokines in the kidneys, vessels and the heart (Hahn et al., 1994; Tummala et al., 105 
1999). Consequently, chronic infusion of AII has been associated with increased BP, 106 
myocardial infiltration of inflammatory cells, and cardiac fibrosis (Qi et al., 2011). Many of 107 
these pathophysiological changes can be attributed to mechanical injury from elevated 108 
BP and AII-induced oxidative stress (Weir, 2006), and will eventually result in end-organ 109 
damage manifested by myocardial infarction, CHF, and chronic kidney disease (CKD) 110 
(Chobanian et al., 2003). The pro-inflammatory and pro-fibrotic effects of the RAAS are 111 
also mediated by ALD, which further promotes insulin resistance and vascular remodeling 112 
(Martinez, 2010; Cascella et al., 2010).  113 
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While the relation of systemic hypertension (HT) to the development of CKD has not been 114 
extensively documented in small animals, there is reasonable evidence to justify 115 
extrapolation of these considerations from human to dog patients (Lefebvre et al., 2007). 116 
In humans, the degree of activation of the renin-angiotensin aldosterone cascade is 117 
related to the severity of heart failure (Swedberg et al., 1990; MacFadyen et al., 1999). In 118 
this population of patients, AII concentrations vary from less than 10 pg/mL in mild cases 119 
of CHF, to 70 pg/mL in seriously affected individuals (Van de Wal et al., 2006). AII is 120 
viewed as a primary determinant of end-organ damage (Roig et al., 2000), while ALD is 121 
known to worsen AII tissue-damaging properties (Rocha et al., 1999). Thereof, elevated 122 
exposure to AII and ALD has been associated with a poor prognosis in multiple case 123 
studies (Roig et al., 2000; Latini et al., 2004). Swedberg et al. (1990) have found a positive 124 
correlation between mortality and levels of AII (P < 0.05) and ALD (P < 0.003) in a group 125 
of severe CHF patients. More recently, a 12 months follow-up study showed that AII was 126 
a significant predictor of death or new heart failure episodes in patients with left ventricular 127 
dysfunction (Roig et al., 2000). Likewise, high ALD concentrations were found to be a 128 
predictor of increased mortality risk that provides complementary prognostic value in a 129 
prospective cohort experiment of 294 patients with CHF of any cause and severity (Güder 130 
et al., 2007).  131 
Compared with the depth of data from the human literature, only limited information on 132 
the relation of AII and ALD to a morbidity and mortality risk is presently available in dogs. 133 
Knowlen et al. (1983) have established a direct relationship between ALD and the clinical 134 
status of dogs suffering from heart failure. Results from Bernay et al. (2010) in a 135 
multicenter prospective trial indicate that ALD receptor antagonism decreases the risk of 136 
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cardiac death, euthanasia, or severe worsening in dogs with moderate to severe MMVD. 137 
Ovaert et al. (2010) suggest that patients with elevated AII and ALD could benefit from 138 
additional therapy with AII receptor blockers (ARBs), or MRAs. However, ALD escape 139 
has also been reported during long-term use of ARBs and MRAs (Naruse et al., 2002; 140 
Rousseau et al., 2002). In a study by Naruse et al. (2002), ALD increased above pre-141 
treatment levels after 8 weeks of ARB administration, causing end-organ damage and left 142 
ventricular hypertrophy in rodents. In addition, results from the RALES Neurohormonal 143 
sub-study (Rousseau et al., 2002) showed a significant increase in AII and ALD over time 144 
(P = 0.003 and P = 0.001, respectively) in spironolactone-treated CHF patients.  145 
ACE Activity is not a Reflective Measure of RAAS Suppression 146 
ACE inhibitors have constituted a breakthrough therapeutic option in the management 147 
of cardiovascular diseases in human and veterinary patients (Pfeffer et al., 1992; BENCH 148 
Study Group, 1999). Earlier investigations on the use of benazepril in dogs have 149 
established that benazeprilat produces a complete and long-lasting inhibition of ACE. In 150 
a study by King et al. (1995), oral administrations of benazepril (0.25 mg/kg q24 h) were 151 
responsible for more than 85% inhibition of ACE during 24 hours. In addition, Toutain and 152 
Lefebvre (2004) have shown that an oral daily dose of 0.125 mg/kg benazepril causes 153 
inhibition of the entire systemic ACE pool within 48 hours.  154 
However, results from our group (Mochel et al., 2013a, Mochel et al., 2015) demonstrate 155 
that benazeprilat triggers a marked fall in AII and ALD, but for a much shorter period of 156 
time, which is consistent with earlier observations in human patients (Lijnen et al., 1982; 157 
Jorde et al., 2002). According to Van de Wal et al. (2006), 45% of severe CHF patients 158 
experience elevated AII levels independent of serum ACE activity. In individuals with 159 
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high ACE activity, non-compliance should be considered along with inadequate dose 160 
selection as potential explanations. Yet, in patients with low measurable ACE activity, this 161 
could be related to the production of AII by up-regulation of ACE independent pathways 162 
(Fyhrquist and Saijonmaa, 2008), in response to renin activation and accumulation of AI 163 
during short and long-term use of ACE inhibitors (Geary et al., 1992). Enzymes other than 164 
ACE may contribute to the conversion of AI to AII. Chymase, cathepsin G, tonin and other 165 
proteases have been described as alternative pathways of AII production (Roig et al., 166 
2000). Our findings on ALD are also in agreement with earlier reports from the veterinary 167 
(Knowlen et al., 1983; Koch et al., 1994) and human literature (Lijnen et al., 1982; Cleland 168 
et al., 1984). Because AII is a known driver of ALD biosynthesis (McCaa et al., 1980), the 169 
partial suppression of AII in ACE inhibitor-treated dogs may account for the insufficient 170 
suppression of systemic ALD levels. Moreover, the possibility of an enhanced sensitivity 171 
of the adrenal glands to AII during chronic ACE inhibitor usage cannot be discarded 172 
(Lijnen et al., 1982). Finally, like all ACE inhibitors, benazeprilat has the potential to induce 173 
natriuresis and potassium retention, which can further stimulate secretion of ALD from 174 
the adrenals.  175 
Role of Cortisol in Disease Development 176 
Cortisol is an endogenous glucocorticoid secreted in conditions of physiologic or 177 
pathologic stress or inflammation. Most of cortisol’s physiologic actions are genomic 178 
effects mediated by binding to intracellular glucocorticoid receptors (GRs). Effects 179 
of GR stimulation on metabolic and immune pathways allow the body to withstand stress 180 
and inflammation. Specific functions of glucocorticoids include stimulation of 181 
gluconeogenesis, mobilization of protein and fat stores, stabilization of lysosomal 182 
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membranes and capillary walls, and decreased migration or function of white blood cells 183 
and other immune system components.  184 
Although aldosterone is typically considered the “target ligand” for MRs, cortisol actually 185 
binds MRs with the same affinity as aldosterone, and circulating concentrations of 186 
free cortisol are 100-200 times higher than aldosterone (Levine et al., 1982; Broqvist et 187 
al., 1989). In healthy patients, cortisol simply occupies the MR binding site without 188 
activating the receptor. In non-renal tissues, such as the heart and vasculature, this tonic 189 
inhibitory binding capability is conferred by the enzyme 11β-hydroxysteroid 190 
dehydrogenase type II (11βHSD2) (Aronson, 2003). However, in inflamed or hypoxic 191 
tissues, 11βHSD2 function is impaired by abnormal oxidation-reduction potential, and 192 
cortisol is able to activate MRs and mimic the actions of aldosterone (Ettinger et al., 193 
1998; Dooley et al., 2012).  194 
In humans with chronic CHF, both cortisol and aldosterone are independent and 195 
complementary predictors of increased mortality, with high levels of both hormones 196 
associated with the worst prognosis (Güder et al., 2015). Another study of humans with 197 
acute decompensated CHF demonstrated that the prognostic value of these biomarkers 198 
depended on whether patients were receiving MRBs (Tidholm et al., 2005). In patients 199 
not receiving MRBs, both aldosterone and cortisol were again independent and 200 
incremental predictors of outcome. However, in MRB-treated patients, only aldosterone 201 
remained a significant predictor of mortality; cortisol was no longer associated with 202 
outcome (Tidholm et al., 2005). These findings suggest that the pharmacologic benefit 203 
of blocking MRs may have more to do with blocking cortisol than with blocking 204 
aldosterone, and that measures of RAAS activation (such as aldosterone levels) alone 205 
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may have limited value in determining whether a patient will benefit from MRBs. While 206 
previous studies have established the prognostic value of cortisol in human CHF, the 207 
effects of endogenous cortisol levels in canine CHF remain unknown.  208 
Established Pharmacological Targets in the Treatment of Canine CHF 209 
Inhibition of the RAAS, as part of a global therapeutic scheme to decrease AII and 210 
ALD exposure, and to lower BP for preventing, or delaying end-organ damage, has 211 
proved to be effective in human and canine CHF (Chobanian et al., 2003; Lefebvre et al., 212 
2007). Among RAAS inhibitors, two classes of drug directly target AII through 213 
complementary modes of action: i) ACE inhibitors prevent the formation of AII and the 214 
degradation of bradykinin, which increases the stimulation of nitric oxide and has positive 215 
effects on endothelial function, while ii) Angiotensin Receptor Blockers (ARBs) 216 
selectively antagonize AII at AT1 receptors. A theoretical advantage of ARBs lies in their 217 
ability to increase activation of the AT2 receptor, and modulate the effects of AII 218 
breakdown products (Liu et al., 1997), while reducing the risk of ALD escape. In practice 219 
though, an escape phenomenon has also been reported during long-term use of ARBs. 220 
In a study by Naruse et al. (2002), ALD increased above pre-treatment levels after 8 221 
weeks of ARB administration, causing end-organ damage and left ventricular hypertrophy 222 
in rodents. Although non-peptide ARBs have found extensive applications in the 223 
treatment of cardiovascular disorders in human medicine, their use in small animal 224 
patients has proven ineffective (Adams, 2009).  225 
By decreasing systemic vascular resistance, ACE inhibitors are known to improve cardiac 226 
hemodynamics and exercise capacity in human and dog patients (Levine et al., 1984; 227 
Uretski et al., 1988; Lefebvre et al., 2007). Benazepril, enalapril, imidapril, and ramipril 228 
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are currently approved for use in dogs with CHF. Of note, multiple studies have shown 229 
that imidapril was non-inferior to enalapril and benazepril (Amberger et al., 2004; Besche 230 
et al., 2007). Benazepril hydrochloride (Fortekor®; Novartis Animal Health, Basel, 231 
Switzerland), is a non-sulfhydryl prodrug which is converted in vivo by esterases into its 232 
active metabolite, benazeprilat, a highly potent and selective inhibitor of ACE (Webb et 233 
al., 1990) with well-documented effectiveness in symptomatic canine CHF (King et al., 234 
1995; Lefebvre et al., 2007). In the BENCH Study (1999), the mean survival time of 235 
benazepril-treated dogs with mild to moderate CHF was improved by a factor of 2.7, as 236 
compared with the placebo group (428 vs. 158 days). A significant gain in exercise 237 
tolerance and clinical condition was also reported after 28 days of treatment. The 238 
favorable outcome of most CHF canine patients under ACE inhibition therapy, despite a 239 
potential incomplete reduction in AII and ALD, suggests that ACE inhibitors exert 240 
additional beneficial effects than AII suppression in the course of heart disease (The 241 
CONSENSUS Trial Study Group, 1987; Pfeffer et al., 1992). As pointed out by Brown and 242 
Vaughan (1998), inhibition of bradykinin degradation, which results in a subsequent gain 243 
in left ventricular relaxation and systolic dysfunction, may account for the clinical 244 
effectiveness of ACE inhibitors. Along with its effect on ACE inhibition and bradykinin 245 
degradation, the blood pressure-lowering action of benazepril could also drive part of the 246 
reported clinical efficacy. Cardiac remodeling is a known deleterious consequence of 247 
arterial hypertension (Azibani et al., 2012), and benazepril (2 mg/kg q24 h P.O, for 2 248 
weeks) has been shown to reduce blood pressure significantly (P < 0.05) in a dog model 249 
of renal hypertension (Mishina and Watanabe, 2008).  250 
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While the use of ACE inhibitors in symptomatic stages of CHF is well-accepted, data 251 
supporting their use in asymptomatic stages (ACVIM A and B) are more sparse. In a study 252 
by Kvart et al. (2002), long-term treatment with enalapril (0.25-0.5 mg q24h P.O) in 229 253 
Cavalier King Charles with asymptomatic MMVD did not delay the onset of heart failure. 254 
Yet, another prospective study by Atkins et al. (2007) in 124 dogs (23 breeds) with MMVD 255 
(ACVIM Stage B2) did show a trend toward benefit in time to onset of CHF (primary 256 
endpoint, P = 0.06) and a significant improvement in all-cause mortality (P < 0.02) with 257 
enalapril treatment (0.45 mg/kg q24h P.O). Finally, the positive effect of ACE inhibition in 258 
preclinical MMVD (ACVIM Stage B1) was further supported by a retrospective study from 259 
Pouchelon et al. (2008). Likewise, benazepril was shown to significantly delay the time to 260 
onset of overt DCM in a retrospective analysis by O’Grady et al. (2009) including 91 261 
Doberman Pinchers. 262 
As opposed to ACE inhibitors, a great body of data has accumulated over the years to 263 
support the use of the inodilator Pimobendan, a selective inhibitor of phosphodiesterase 264 
3, in preclinical stages of heart failure. The recently completed EPIC study enrolling 360 265 
dogs with Stage B2 MMVD showed that chronic administration of pimobendan 266 
significantly delayed the preclinical period (P = 0.0038) as compared with placebo (1228 267 
days vs. 766 days). Of note, the effect of pimobendan vs. enalapril in symptomatic stages 268 
of MMVD and DCM was compared in a pivotal double-blinded trial from the FDA (FDA, 269 
2007). No apparent differences in the primary endpoint (treatment success) were reported 270 
between study groups and the estimated mortality (14% death) was identical between 271 
pimobendan and enalapril. Another study (QUEST) by Haggstrom et al. (2008) comparing 272 
pimobendan (0.4-0.6 mg/kg q24h P.O) and benazepril (0.25-1 mg/kg q24h P.O) in 226 273 
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dogs with MMVD found a modest benefit in survival in dogs receiving the inodilator 274 
(hazard ratio = 0.688, P < 0.01). 275 
More recently, Mineralocorticoids Receptor Antagonists (MRAs) have also been 276 
registered for use in canine patients suffering from CHF. Although Schuller et al. (2011) 277 
could not find any significant effect of low-dose spironolactone (0.5 mg/kg q24h P.O) on 278 
survival when used as adjunct treatment to conventional CHF therapy, a subsequent 279 
study by Bernay et al. (2010) did show a significant reduction in risk or cardiac morbidity 280 
and mortality with the use of higher spironolactone dosage (2 mg/kg q24 h, P.O). In this 281 
study, spironolactone reduced by a factor of ca. 2 the risk of cardiac-related death, 282 
euthanasia, or severe worsening when used in addition to conventional therapy (ACE 283 
inhibition, plus furosemide and digoxin if required) in dogs with MMVD. These results 284 
were however disputed by Kittleson & Bonagura (2010) on the grounds of possible 285 
methodological flaws such as bias in  patient categorization. In humans, MRAs have been 286 
associated with a significant reduction in mortality in human CHF patients when combined 287 
with ACE inhibitors, whereas ARBs have not (Werner et al., 2010). These positive 288 
outcomes support the current recommendation of the use of MRAs in the treatment of 289 
human CHF with reduced ejection fraction (Butler et al., 2012).  290 
In a study by Chen et al. (2016) in humans with diastolic heart failure (NYHA Grade 1 and 291 
2), spironolactone (40 mg q24h P.O) significantly improved clinical symptoms when 292 
associated with low-dose furosemide (20 mg q24h P.O). Furosemide is a cornerstone in 293 
the treatment of heart failure in human and veterinary medicine, but its use is typically 294 
associated with a significant elevation of ALD levels (Mochel and Fink, 2012). The positive 295 
effect of combined furosemide/spironolactone could therefore be related to the direct 296 
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receptor antagonism of ALD in the context of RAAS activation. Torasemide (also referred 297 
to as torsemide) is a recently developed loop diuretic with a more potent and long-lasting 298 
effect than furosemide (Uechi et al., 2003; Hori et al., 2007). In addition, results from the 299 
TORIC study in humans with CHF demonstrated the superiority of torasemide over other 300 
diuretics (including furosemide) on patient mortality (Cosin et al., 2002). In a short-term 301 
term clinical trial of 366 dogs with MMVD (TEST study), Chetboul et al. (2017) showed 302 
that torasemide (0.24 mg/kg q24h P.O) was associated with a 2-fold reduction in risk of 303 
reaching a composite cardiac endpoint (spontaneous cardiac death, euthanasia due to 304 
heart failure or CHF class worsening) as compared with furosemide (P < 0.05). Results 305 
from Lopez et al. (2004) suggest that torasemide, but not furosemide, significantly reduce 306 
myocardial fibrosis; a mechanism that they later attributed to a reduction of PCP 307 
(Procollagen type I Carboxy-terminal Proteinase) activation, an enzyme involved in 308 
Collagen type I formation (Lopez et al., 2007).  309 
Future Directions 310 
Chronopharmacotherapy: Making the Best Use of Available Drug Therapies 311 
Deeper understanding of circadian rhythms can have a substantial impact on the 312 
therapeutic management of RAAS-related diseases by determining the time of drug 313 
administration that would optimize efficacy while minimizing the occurrence of adverse 314 
effects. This concept, referred to as chronotherapy, is currently being used for the 315 
treatment of human rheumatoid arthritis (Staessen et al., 1992), lung cancer (Mazzoccoli 316 
et al., 2012) and cardiovascular diseases (Nicholls et al., 1993). An increasing number of 317 
investigations on the use of ACE inhibitors in hypertension have shown a greater 318 
reduction of BP with bedtime administration as compared with morning dosing (Palatini 319 
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et al., 1992; Hermida & Ayala, 2009). Sole and Martino (2009) have demonstrated that 320 
heart and vessels growth and remodeling were dynamic and occurred more actively 321 
during the period normally allocated to sleep. In mice, administrations of the ACE inhibitor 322 
captopril at sleeping hours significantly improved cardiovascular function and reduced 323 
adverse remodeling, while no effects were reported when the drug was given during 324 
active hours of the day (Martino et al., 2011). In a study by Nozawa et al. (2006), 325 
temocapril (another ACE inhibitor) prolonged the survival of spontaneously hypertensive 326 
rats, with a maximum effect after dosing during the resting period, and a minimum effect 327 
after dosing at the active period. The authors concluded that treatment with an ACE 328 
inhibitor at night may be a more effective dosing regimen in patients with hypertension.  329 
Another therapeutic approach in the management of heart failure and hypertension is to 330 
continuously assess not only the medical response, but also the development of adverse 331 
effects. The optimal treatment time can vary considerably between patients, as shown by 332 
the work of Watanabe et al. (2006, 2013) in hypertensive patients under 333 
losartan/hydrochlorothiazide (L/H) (angiotensin II receptor blocker/thiazide diuretics) 334 
combination therapy. In their study, L/H taken few hours before bedtime in a 61-year-old 335 
man induced circadian hyper-amplitude-tension (CHAT), a condition associated with an 336 
increased cardiovascular disease risk. For yet another patient, CHAT was exacerbated 337 
when L/H was given during the day, but was alleviated when the same dose of treatment 338 
was taken in the evening. In all instances, optimization of therapy based on the most 339 
appropriate time of drug administration should be investigated on an individual basis. 340 
Until recently, no detailed information on the systems dynamics of the renin cascade was 341 
available in dogs. Research performed within our group presents the first description of 342 
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the chronobiology of the canine RAAS in relation to BP, renal sodium/potassium handling, 343 
and feeding schedules using a NLME modeling approach (Mochel et al., 2013a, 2014). 344 
This model-based approach provided new insights into the relation of dietary sodium to 345 
RAAS chronobiology, which would have been impossible using standard statistics. 346 
Specifically:  347 
i) The amount of sodium intake was shown to influence the tonic (i.e. mesor) 348 
and the phasic (i.e. amplitude) secretion of renin; the greater the intake of 349 
sodium, the smaller the mesor and amplitude of RA; 350 
ii) The time of food (i.e. sodium) intake appeared to exert a synchronizing effect 351 
on the acrophase of RA and BP oscillations, which consolidates preliminary 352 
findings from the literature (Itoh et al., 1996).  353 
Based on our findings on the dynamics of the circulating RAAS under physiological 354 
(Mochel et al., 2013a, 2014a), and RAAS-activated conditions (Mochel et al., 2013b, 355 
2014b), various strategies could therefore improve therapeutic management of 356 
cardiovascular diseases in dogs. Essentially, one could think of:  357 
i) Adjusting the time of dosing. In dogs, cardioactive medications are 358 
commonly given with morning food for the sake of convenience. However, 359 
results from our chronobiological investigations with morning feeding indicate 360 
that the peak RA and BP occurs in the evening and at night. Assuming that 361 
drug efficacy is maximum when the peak effect time is synchronized with the 362 
peak of the underlying biological rhythm, one would expect optimized efficacy 363 
with bedtime dosing and morning feeding (or vice versa);  364 
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ii) Adjusting dietary sodium intake. Since high dietary sodium is thought to play 365 
a role in the development of HT, cardiovascular and renal diseases in humans, 366 
a common practice in veterinary cardiology was to restrict sodium intake in the 367 
diet of CHF dogs. There is however no substantial evidence that elevated 368 
sodium intake increases the risk of HT in dogs (see results from Anderson et 369 
al., 1986 and Greco et al., 1994 showing that fluctuations in sodium intake has 370 
no apparent effect on BP and heart rate), and the current recommendation is 371 
to avoid highly elevated dietary salt intake, without making a specific effort to 372 
restrict it (Chandler, 2008). Furthermore, because the mesor and amplitude 373 
value of RA oscillations was found to be much greater in dogs fed a low-sodium 374 
regime (Mochel et al., 2014b) we could assume that CHF dogs would rather 375 
benefit from a normal, not a restricted-sodium diet.  376 
Taken together, our results suggest that additional research on the chronobiology of the 377 
RAAS is required in small animal patients to further improve therapeutic management of 378 
CHF in dogs by selecting the appropriate time of treatment.  379 
Learning from Human Pharmaceutical R&D 380 
Old Targets, New Drugs 381 
Although spironolactone is relatively inexpensive, its use has been associated with 382 
multiple side effects in humans, including gynecomastia in men (Mosenkis and 383 
Townsend, 2004). This is due to the ability of spironolactone to bind to other steroid 384 
hormone receptors. To minimize the likelihood of such effects, more selective MRAs have 385 
been developed, such as eplerenone (2nd MRA generation) and finerenone (3rd MRA 386 
generation). The next generation will provide even greater selectivity towards the MR, 387 
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while targeting select tissues to further improve the benefit-risk ratio of MRAs (Ames et 388 
al., 2019). 389 
First generation Renin Inhibitors (RIs), such as aliskiren have shown disappointing 390 
results for the treatment of cardiovascular (ASTRONAUT and ATMOSPHERE trials) and 391 
renal diseases in humans (Gheorghiade et al., 2013; McMurray et al., 2016). The next 392 
generation of RIs is currently under development. Finally, previously developed 393 
Aldosterone Synthase Inhibitors (ASIs) lacked selectivity and were discontinued 394 
(Calhoun et al., 2011).  395 
New Therapeutic Targets 396 
1. Recently Approved Therapeutics: Sacubitril/Valsartan 397 
Sacubitril/valsartan (Entresto®) is a first-in-class angiotensin receptor 398 
neprilysin inhibitor (ARNI), which upon oral administration delivers systemic exposure to 399 
sacubitril (AHU377) and valsartan, a well-established ARB recommended by established 400 
guidelines for the treatment of HF (McMurray et al., 2012; Langenickel & Dole, 2012; 401 
Yancy et al., 2013). Sacubitril is an inactive prodrug that is rapidly hydrolyzed by carboxyl 402 
esterase 1 to sacubitrilat, a pharmacologically active NEP inhibitor [23]. Lately, results of 403 
the Phase III PARADIGM-HF clinical trial comparing Entresto® with enalapril in patients 404 
with reduced ejection fraction CHF were disclosed in the New England Journal of 405 
Medicine (McMurray et al., 2014). Entresto® was found to be superior by ca. 20% to 406 
enalapril in reducing the risks of death and of hospitalization for heart failure (P < 0.001). 407 
Entresto® has now been approved in many countries for the treatment of HFrEF and is 408 
recommended by European and American HF guidelines (Ponikowski et al., 2016; Yancy 409 
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et al., 2016) for the treatment of chronic symptomatic HFrEF (New York Heart Association 410 
Class II–IV).  411 
A preliminary dog study examined the effects of sacubitril/valsartan (225 and 675mg/day) 412 
vs. placebo, sacubitril (360mg/day), valsartan (900mg/day), and benazepril (5mg/day) on 413 
the dynamics of the renin-angiotensin-aldosterone system (RAAS) and the natriuretic 414 
peptide (NP) system in dogs. Beagle dogs (N = 18) were fed a low-salt diet (0.05% Na) 415 
for 15 days to model RAAS activation observed in clinical heart failure. Drugs were 416 
administered once daily during the last 10 days, while the effects on the RAAS and NPs 417 
were assessed on Day 1, 5, and 10 (Mochel et al., 2014, 2018). Compared with placebo, 418 
sacubitril/valsartan (675mg) substantially increased cGMP circulating levels, while 419 
benazepril and valsartan showed no effect. Additionally, sacubitril/valsartan (675mg) and 420 
valsartan significantly increased plasma renin activity, angiotensin I and angiotensin II 421 
concentrations. Finally, sacubitril/valsartan (both doses), and valsartan significantly 422 
decreased plasma aldosterone vs. placebo. Systemic exposure to valsartan following 423 
sacubitril/valsartan 675mg administration was similar to that observed with valsartan 424 
900mg administration alone.  425 
These results were later confirmed in a small prospective, randomized clinical study of 426 
sacubitril/valsartan (20 mg/kg q12h P.O) in 13 dogs with MMVD showing a significant 427 
reduction in urinary aldosterone to creatinine ratio vs. placebo (P = 0.032) (Newhard et 428 
al., 2018). These positive findings in dogs suggest that sacubitril/valsartan is a promising 429 
pharmacological candidate for increased survival in canine cardiovascular diseases.  430 
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2. Drugs Showing Encouraging Results in Human Clinical Trials 431 
The vast majority of ongoing clinical trials in human patients with heart failure 432 
are being conducted in HFrEF. Therefore, this paragraph exclusively focuses on current 433 
advances in this patient population. A list of novel pharmacotherapeutic modalities 434 
investigated in pre-clinical and clinical HFrEF studies is provided in Selim et al. (2017). 435 
Omecamtive Mecarbil. Omecamtive Mecarbil (OM) is different from other 436 
inotropes as its mode of action is independent of Ca2+ intracellular increase. As such, OM 437 
has been shown to improve myocardial systolic function without a concomitant increase 438 
in oxygen consumption (Selim et al., 2017). In the COSMIC-HF Phase II, placebo-439 
controlled trial including 448 patients with HFrEF, OM showed a concentration-dependent 440 
improvement in myocardial function (Teerlink et al., 2016). Launching of the Phase III 441 
program was announced in the fall of 2016. 442 
Empaglifozin. Empaglifozin (EG) is an anti-diabetic medication that selectively 443 
inhibits the sodium glucose cotransporter 2 (Heise et al., 2013), while acting as an osmotic 444 
diuretic to reduce systemic BP (Tikkanen et al., 2015). A post-hoc analysis of the EMPA-445 
REG OUTCOME trial looking at a subgroup of 706 patients with HF at baseline showed 446 
a significantly lower rate of cardiovascular death and HF hospitalization in type 2 diabetes 447 
patients receiving EG vs. placebo (Fitchett et al., 2016). A clinical trial is currently 448 
underway to investigate the effect of EG in CHF patients with or without diabetes. 449 
SERCA2 Activator. SERCA2 is a specialized Ca2+ pump that is responsible 450 
for calcium reuptake in the sarcoplasmic reticulum. The CUPID study was designed to 451 
evaluate the efficacy of gene transfer using adeno-associated virus (AAV1) for delivery 452 
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of SERCA2 cDNA in patients with HF (Jessup et al., 2011). A follow-up trial (SERCA-453 
LVAD) is currently underway. 454 
CD-NP. CD-NP is a synthetic NP causing vasodilation with minimal effect on 455 
BP. In addition, CD-NP has demonstrated an inhibitory effect on myocardial fibrosis in 456 
end-stage HF patients (Ichiki et al., 2014), as well as ALD production in healthy subjects 457 
(Lee et al., 2009). 458 
Urocortin-2. Urocortin-2 (U2) is a member of the CRF (Corticotropin-Releasing 459 
Factor) family with a high affinity to the CRF receptor. U2 was shown to improve 460 
myocardial function in animal models of HF. A preliminary clinical trial of 53 patients with 461 
acute HF showed promising results (Chan et al., 2013), however larger studies in patients 462 
with chronic HF are warranted to further evaluate the benefit of U2 in CHF. 463 
Conclusions 464 
In conclusion, modulation of the renin-angiotensin aldosterone cascade remains the 465 
treatment of choice for management of chronic heart failure in human and veterinary 466 
medicine. Administration of therapeutic drugs at a time where they are most likely to be 467 
effective and/or best tolerated using chronobiological approaches has the potential to 468 
significantly increase the efficiency of RAAS inhibitors at no extra-cost. As shown in other 469 
therapeutic classes (Fink et al., 2012; Pelligand et al., 2016; Riviere et al., 2016; Lin et 470 
al., 2016; Bon et al., 2018), pharmacokinetic-pharmacodynamic modeling is an attractive 471 
tool to integrate the large body of information on RAAS physiology, regulation and 472 
modulation for the selection of relevant therapeutic doses (Hallow et al., 2014; Martinez 473 
et al., 2018). Canines have long been used for the preclinical testing of human 474 
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cardioactive drugs and represent an attractive spontaneous disease model to study 475 
innovative therapeutic strategies. In return, information on new therapeutic targets for 476 
CHF from human clinical trials can guide the development of future therapeutic 477 
candidates in veterinary cardiology, under the so-called ‘One Health’ initiative (Schneider 478 
et al., 2018).  479 
Sacubitril/valsartan has recently been given Class I recommendation, the strongest 480 
endorsement, in updated clinical practice guidelines simultaneously released by the 481 
American College of Cardiology, the American Heart Association and the Heart Failure 482 
Society of America in the US. Guidelines now establish sacubitril/valsartan as standard 483 
of care for HFrEF. Preliminary efficacy and safety findings in disease models of RAAS 484 
activation and clinical patients are encouraging in dogs but deserves further investigation 485 
in larger patient cohorts. Another promising combination is the association of loop 486 
diuretics with aldosterone receptor antagonists, such as spironolactone. Given the proven 487 
benefit of torasemide over furosemide and the improved selectivity of the most recent 488 
MRAs, the combination of eplerenone and torasemide could be evaluated in dogs with 489 
CHF. Finally, positive findings from the COSMIC-HF program on myocardial function in 490 
HFrEF also positions Omecamtive mecarbil as an attractive target for the treatment of 491 
canine CHF.  492 
  493 
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